In addition, recent evidence suggests that use of aromatase inhibitors in women with hormone receptor positive breast cancer may increase the risk of heart failure, compared to tamoxifen (Khosrow-Khavar et al., 2020). This evidence concerns the gene CYP19A1 and heart failure.